Similar articles for PMID: 41369248

Year	Number of Results
2014	3
2015	2
2017	3
2018	3
2019	6
2020	8
2021	18
2022	11
2023	18
2024	17
2025	22
2026	2

1

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy.

Hu S, Wu Z, Dai Y, Shi X, Hu Q, Liu C, Zhu Y, Yu R, Li J, Liu Y, Liu T, Lu L, Yao C, Shen B, Shi M, Chen C, Wang X, Zhou G. Hu S, et al. Cancer Biol Med. 2025 Dec 10;22(12):1544-52. doi: 10.20892/j.issn.2095-3941.2025.0393. Cancer Biol Med. 2025. PMID: 41369248 Free PMC article. No abstract available.

2

Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure.

Kaira K, Kobayashi K, Shiono A, Yamaguchi O, Hashimoto K, Mouri A, Shinomiya S, Miura Y, Imai H, Kagamu H. Kaira K, et al. Thorac Cancer. 2021 Mar;12(6):864-873. doi: 10.1111/1759-7714.13864. Epub 2021 Jan 31. Thorac Cancer. 2021. PMID: 33522139 Free PMC article.

3

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.

Yamada Y, Imai H, Sugiyama T, Minemura H, Kanazawa K, Kasai T, Minato K, Kaira K, Kaburagi T. Yamada Y, et al. Medicina (Kaunas). 2021 Sep 3;57(9):929. doi: 10.3390/medicina57090929. Medicina (Kaunas). 2021. PMID: 34577852 Free PMC article.

4

Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.

Kuiper JL, Heideman DA, Würdinger T, Grünberg K, Groen HJ, Smit EF. Kuiper JL, et al. Clin Lung Cancer. 2015 Jan;16(1):60-6. doi: 10.1016/j.cllc.2014.07.008. Epub 2014 Aug 15. Clin Lung Cancer. 2015. PMID: 25242669 Clinical Trial.

5

Impact of sequential (first- to third-generation) EGFR-TKI treatment on corrected QT interval in NSCLC patients.

Gan T, Chen J, Wang H, Shang C, Xi S, Fan Z, He B, Zhang M, Zhao L. Gan T, et al. Front Oncol. 2024 May 7;14:1330165. doi: 10.3389/fonc.2024.1330165. eCollection 2024. Front Oncol. 2024. PMID: 38774407 Free PMC article.

6

Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.

Sonehara K, Tateishi K, Yoh K, Usui K, Hosomi Y, Kishi K, Naka G, Watanabe K, Tamano S, Uemura K, Kunitoh H. Sonehara K, et al. Thorac Cancer. 2025 Jan;16(2):e15507. doi: 10.1111/1759-7714.15507. Epub 2024 Dec 7. Thorac Cancer. 2025. PMID: 39644181 Free PMC article.

7

Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.

Kashiwabara K, Semba H, Fujii S, Tsumura S. Kashiwabara K, et al. Cancer Chemother Pharmacol. 2017 Apr;79(4):705-710. doi: 10.1007/s00280-017-3261-5. Epub 2017 Mar 3. Cancer Chemother Pharmacol. 2017. PMID: 28258422

8

Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.

Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Miyawaki T, et al. Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14. Invest New Drugs. 2021. PMID: 34259953

9

Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world.

Li H, Wang J, Zhang G, Li Y, Lin L, Yang H, Zhou J, Zhang L, Lv D. Li H, et al. J Thorac Dis. 2020 Mar;12(3):550-557. doi: 10.21037/jtd.2019.12.122. J Thorac Dis. 2020. PMID: 32274120 Free PMC article.

10

Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.

Xu J, Zhu A, Xu Y, Zhang Y, Shen Y, Niu Y, Zhong H, Zhong R. Xu J, et al. BMC Cancer. 2025 Dec 22;25(1):1879. doi: 10.1186/s12885-025-15335-x. BMC Cancer. 2025. PMID: 41430586 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 41369248

101 results

Results by year